Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . Lu ye Pharma 绿叶 制药 * ** LUYE PHARMA GROUP LTD . 绿叶 制药 集团 有限公司 ( Incorporated in Bermuda with limited liability ) ( Stock Code : 02186 ) ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 FINANCIAL HIGHLIGHTS Revenue decreased by RMB10.5 million or 0.4 % to RMB2,951.7 million , as compared to the six months ended 30 June 2020 . Gross profit decreased by RMB244.2 million or 11.1 % to RMB1,953.7 million , as compared to the six months ended 30 June 2020 , and gross profit margin was 66.2 % . Net profit decreased by RMB132.3 million or 24.5 % to RMB408.0 million , as compared to the six months ended 30 June 2020. Normalised net profit ** decreased by RMB84.7 million or 13.4 % to RMB546.0 million as compared to the six months ended 30 June 2020 . Profit attributable to shareholders decreased by RMB152.8 million or 28.3 % to RMB386.6 million , as compared to the six months ended 30 June 2020. Normalised profit attributable to shareholders ** decreased by RMB105.2 million or 16.7 % to RMB524.6 million as compared to the six months ended 30 June 2020 . EBITDA decreased by RMB207.6 million or 17.9 % to RMB954.7 million , as compared to the six months ended 30 June 2020. Normalised EBITDA * decreased by RMB158.0 million or 13.3 % to RMB1,027.8 million as compared to the six months ended 30 June 2020 . Earnings per share was RMB11.32 cents compared to RMB16.90 cents for the six months ended 30 June 2020 . No interim dividend was proposed by the Board for the six months ended 30 June 2021 . Normalised EBITDA is defined as the EBITDA excluding fair value adjustment of redemption liabilities and fair value adjustment of contingent considerations . Normalised net profit and Normalised profit attributable to shareholders are defined as the net profit and profit attributable to shareholders excluding fair value adjustment of redemption liabilities , fair value adjustment of contingent considerations and convertible bonds interest expense . - 1 -